WASHINGTON: An expert panel on health recommended the Biden administration to resume the use of the Johnson & Johnson Covid-19 vaccine after an 11-day pause.
The panel is said to have found the single-dose Covid-19 shot of Johnson & Johnson has lower chances of blood clotting and it has advised the Food and Drug Administration and the Centers for Disease Control and Prevention to continue the vaccination.
Health authorities in the United States on April 14 had proposed a halt on the vaccine following instances of severe blood clots among a handful of the millions of Americans who received the vaccine.
"We have concluded that the known and potential benefits of the Janssen Covid-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older," said Janet Woodcock, head of FDA in a joint statement with the CDC.
CDC head Rochelle Walensky said "exceptionally rare events" of clotting were identified, adding that regulators will continue to monitor the rollout of the vaccines.
According to data presented Friday, of 3.9 million women who got the Johnson & Johnson shot, 15 developed serious blood clots and three died.
The majority of the confirmed cases, 13 of the 15, was aged under 50 years old. There were no reported cases among men. Europe's medicines regulator said Tuesday that blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine.
The regulator said its safety committee "concluded that a warning about unusual blood clots with low blood platelets should be added to the product information" for the J&J shot.